Loading...
Market
How many countries will approve Elevidys by end of 2024?
2
Resolution / Starting Odds
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
Official announcements from Sarepta Therapeutics and international regulatory bodies
Story
FDA Expands Approval of Sarepta's Elevidys Gene Therapy for Duchenne Muscular Dystrophy for Ages 4 and Above
Jun 20, 2024, 09:44 PM
The U.S. Food and Drug Administration (FDA) has expanded the approval of Sarepta Therapeutics' gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) patients aged four and above. The expanded approval now includes both ambulatory and non-ambulatory patients, with the non-ambulatory indication under accelerated approval and the ambulatory indication converted to full approval. This decision allows nearly all children suffering from DMD, a rare condition that can leave infants unable to walk, to access the treatment. Elevidys targets patients with a confirmed mutation in the DMD gene.
View original story
Similar markets
None • 33%
1-3 • 33%
More than 3 • 33%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Less than 10 • 25%
10-20 • 25%
20-30 • 25%
More than 30 • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%